Medtronic plc and Stryker Corporation are two of the largest names in the global medical-device industry, yet they appeal to different types of investors. Medtronic (MDT) is a diversified, dividend-oriented stalwart working through a multi-year turnaround, while Stryker (SYK) is a higher-growth, robotics-led growth story trading at a premium. This stock comparison examines relative performance, growth drivers, risk factors, and market positioning to help traders and long-term investors assess which profile better fits the current market environment. Both companies serve the same underlying tailwind — aging demographics and rising procedural volumes — but their financial profiles and momentum differ meaningfully.
Medtronic plc (MDT) develops and sells device-based therapies across cardiovascular, neuroscience, medical-surgical, and diabetes businesses, with roughly half of its sales generated outside the United States. In recent weeks, the company's stock has strengthened, approaching the upper end of its 52-week range. The catalyst was a stronger-than-expected quarterly report in which revenue and adjusted EPS (earnings per share) topped consensus, led by the cardiovascular and diabetes segments.
Management raised full-year organic revenue growth guidance to approximately 5.5%, and sell-side responses have turned more constructive, including an upgrade from a previously bearish stance. Analysts point to an improving product pipeline and reaccelerating investment in research and development. Still, operating margins have been uneven as the company reinvests for growth, and it carries a comparatively heavy debt load. This mix of improving momentum and lingering margin pressure defines MDT's current market positioning.
Stryker Corporation (SYK) is a medical-technology leader focused on orthopedics, surgical equipment, and neurotechnology, and is best known for its Mako robotic-assisted surgery platform, whose global installed base now exceeds 3,000 systems. Recent market activity reflects a company sustaining double-digit organic growth, with full-year sales surpassing $25 billion and both earnings and cash flow expanding.
Growth has been broad-based, led by instruments, endoscopy, and medical products, while the orthopedics business benefits from record robotic installations and rising utilization. The company has also sharpened its portfolio through divestitures and the integration of its peripheral-vascular acquisition. Momentum is supported by healthy hospital capital budgets and an elevated order book. Because of this faster growth, SYK trades at a meaningfully higher valuation multiple than many peers, a premium that hinges on continued execution and robotics adoption.
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI trading bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only the best and most suitable for current market conditions earn a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance history, statistics, and set of tickers, giving traders a range of approaches — from short-term momentum to longer-horizon trend following. The selection is designed to surface the strategies most aligned with prevailing market conditions rather than a one-size-fits-all recommendation. Investors comparing MDT and SYK may find it useful to review how these AI-driven strategies are currently positioning. Visit Trending AI Robots to explore the latest selections.
The core trade-off between these two stocks is growth versus value and income. SYK is generating organic growth of roughly 10% — about double MDT's guided mid-single-digit pace — which justifies its higher price-to-earnings ratio. MDT, by contrast, offers a dividend yield near 3% and a lower multiple, making it more attractive to income- and value-focused investors.
Business-model contrast is also notable. MDT is the more diversified of the two, spanning cardiac rhythm, diabetes, and surgical businesses, which can smooth results but also dilute top-line growth. SYK is more concentrated around orthopedics, surgical equipment, and robotics, where it holds leading positions but faces greater sensitivity to hospital capital-equipment spending cycles.
Risk factors differ as well. MDT carries higher leverage and has seen uneven operating-margin performance amid reinvestment, while SYK's premium valuation leaves less room for disappointment if robotics adoption or procedural volumes slow. Both remain exposed to currency fluctuations and global healthcare-policy shifts, given substantial international revenue bases.
Based on observable factors, Tickeron's AI would likely favor SYK in the current environment. The stock exhibits stronger and more consistent trend momentum, driven by sustained double-digit organic growth, record robotics installations, and an elevated capital order book. While MDT's improving product cycle and recent analyst upgrades are encouraging, its growth remains more moderate and its margin trajectory less certain. A momentum- and trend-oriented AI framework would typically weight relative performance and catalyst consistency heavily, both of which currently favor SYK. That said, MDT's lower valuation and higher yield could appeal to strategies emphasizing stability and income, making the choice dependent on the specific AI bot's trading style and objectives.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MDT declined for three days, in 165 of 300 cases, the price declined further within the following month. The odds of a continued downward trend are 55%.
The 10-day RSI Indicator for MDT moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 14 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 67 cases where MDT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 45%.
MDT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on MDT as a result. In 47 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
The Moving Average Convergence Divergence (MACD) for MDT just turned positive on October 12, 2026. Looking at past instances where MDT's MACD turned positive, the stock continued to rise in 23 of 42 cases over the following month. The odds of a continued upward trend are 55%.
MDT moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MDT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +3.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDT advanced for three days, in 171 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 87 of 237 cases where MDT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 37%.
The Tickeron Price Growth Rating for this company is 20 (best 1 - 100 worst), indicating outstanding price growth. MDT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 51 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.592) is normal, around the industry mean (4.142). P/E Ratio (24.890) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.608) is also within normal values, averaging (11.253). Dividend Yield (0.028) settles around the average of (0.011) among similar stocks. P/S Ratio (3.176) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The 10-day moving average for SYK crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on SYK as a result. In 49 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
SYK moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYK advanced for three days, in 174 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The Aroon Indicator entered an Uptrend today. In 128 of 258 cases where SYK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
The 10-day RSI Indicator for SYK moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 24 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 63%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 59 cases where SYK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 50%.
SYK broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.211) is normal, around the industry mean (4.142). P/E Ratio (33.491) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.253). Dividend Yield (0.011) settles around the average of (0.011) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
MDT | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 85 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 69 | |
SMR RATING 1..100 | 68 | 52 | |
PRICE GROWTH RATING 1..100 | 20 | 49 | |
P/E GROWTH RATING 1..100 | 51 | 79 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (65) in the Medical Specialties industry is in the same range as SYK (79). This means that MDT’s stock grew similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (69) in the Medical Specialties industry is in the same range as MDT (100). This means that SYK’s stock grew similarly to MDT’s over the last 12 months.
SYK's SMR Rating (52) in the Medical Specialties industry is in the same range as MDT (68). This means that SYK’s stock grew similarly to MDT’s over the last 12 months.
MDT's Price Growth Rating (20) in the Medical Specialties industry is in the same range as SYK (49). This means that MDT’s stock grew similarly to SYK’s over the last 12 months.
MDT's P/E Growth Rating (51) in the Medical Specialties industry is in the same range as SYK (79). This means that MDT’s stock grew similarly to SYK’s over the last 12 months.
| MDT | SYK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 54% | 1 day ago 63% |
| Stochastic ODDS (%) | 1 day ago 45% | 1 day ago 56% |
| Momentum ODDS (%) | 2 days ago 55% | 1 day ago 54% |
| MACD ODDS (%) | 2 days ago 55% | N/A |
| TrendWeek ODDS (%) | 1 day ago 53% | 1 day ago 51% |
| TrendMonth ODDS (%) | 1 day ago 50% | 1 day ago 50% |
| Advances ODDS (%) | 15 days ago 54% | 9 days ago 57% |
| Declines ODDS (%) | 7 days ago 55% | 1 day ago 50% |
| BollingerBands ODDS (%) | 1 day ago 49% | 1 day ago 54% |
| Aroon ODDS (%) | 1 day ago 37% | 1 day ago 50% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MDT’s FA Score shows that 1 FA rating(s) are green while SYK’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MDT’s TA Score shows that 6 TA indicator(s) are bullish while SYK’s TA Score has 5 bullish TA indicator(s).
MDT (@Medical/Nursing Services) experienced а -3.67% price change this week, while SYK (@Medical/Nursing Services) price change was -6.77% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.08%. For the same industry, the average monthly price growth was -5.52%, and the average quarterly price growth was -4.54%.
MDT is expected to report earnings on Nov 24, 2026.
SYK is expected to report earnings on Feb 02, 2027.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.